Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform
Sponsor
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
Advance T cell therapy research into the clinic with a novel lipid nanoparticle (LNP) platform. This platform enables cell therapy researchers to establish a clinically-relevant method for ex vivo gene delivery and editing Genetically modifying immune cells against tumors is a promising anti-cancer therapy. However, current gene delivery methods have significant challenges, hindering further innovations in cell therapies. Non-viral electroporation method can be harsh on cells, making it difficult to generate quality cells at high yields, whereas conventional viral vector delivery method is expensive and cumbersome to manufacture.GenVoy-ILM™ T Cell Kit for mRNA, a first-to-market lipid nanoparticle reagent kit, overcomes these limitations to enable RNA delivery into human primary T cells with high efficiency while maintaining high cell viability. This kit can be easily tuned and scaled across the NanoAssemblr® NxGen microfluidic platform from discovery to the clinic.
- Challenges with current ex vivo gene delivery and editing strategies for cell therapies
- Potential of RNA-LNPs in cell therapies
- Introduction of GenVoy™ lipid nanoparticle delivery and NanoAssemblr® microfluidic platform
- Latest proof-of-concept study results
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
Pure and simple: understanding LNP analytics for better mRNA-based drugs
